Maypharm is actively exploring opportunities for partnerships and acquisitions

Sameer Kolhe, President, Maypharm, divulges how his company is leveraging technology-driven products, tailored business models, and niche market strategies to drive growth and address unmet medical needs, in an interview with Lakshmipriya Nair

- Lakshmipriya Nair

Maypharm currently has a strong presence in Brazil and Mexico. What are your plans for expanding into other countries in the near future?

Maypharm has successfully established a strong presence in Brazil and Mexico. The company's strategic focus on entering high-barrier-to-entry markets has positioned it as a key player in the Latin American pharma market. By targeting markets with significant unmet medical needs and complex regulatory landscapes, Maypharm has differentiated itself from competitors and gained a competitive edge. Both these markets together make up to more than 65 per cent of market of Latin America. This approach has allowed us to position ourselves as a serious player in the region and sort of a specialists for these two highly complex markets, not just to get the products registered, but also to have the right business models post registration to add value to the entire supply chain - from the marketing player to the manufacturer.

We're now expanding our operations into Peru, Colombia and other Central/South American and Caribbean countries, but will always have a very specific business model most suitable for the market and conducive for Maypharm's steady growth. By establishing a strong commercial presence, including a dedicated sales force, Maypharm aims to drive sustainable growth and further solidify its position as a leading player in the region.

As a relatively new company in a highly regulated industry, what have been your biggest challenges? How have you worked to mitigate them?